NCT03110484 is a Phase 2 clinical trial of Pemetrexed 500 MG in Biliary Tract Cancer, sponsored by Samsung Medical Center.

Who is sponsoring NCT03110484?

NCT03110484 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03110484?

Interventions in NCT03110484: Pemetrexed 500 MG, Erlotinib.

What condition does NCT03110484 study?

NCT03110484 studies Biliary Tract Cancer.

Is NCT03110484 still recruiting?

NCT03110484 is currently status unknown. Last updated 15 June 2022.

Last reviewed 2022-06-15 · How we verify

NCT03110484

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Status unknown Phase 2 Last updated 15 June 2022

What this trial tests

Phase 2 trial testing Pemetrexed 500 MG in Biliary Tract Cancer in 44 participants. Status unknown.

Timeline

9 July 2021

Primary endpoint
14 June 2023

14 June 2024

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	9 July 2021
Primary completion	14 June 2023
Estimated completion	14 June 2024
Sites	2 locations across South Korea

Drugs / interventions tested

Pemetrexed 500 MG — full drug profile →
Erlotinib (erlotinib) — full drug profile →

Conditions studied

Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

Samsung Medical Center

Who can join

20 and older, any sex, with Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabine containing chemotherapy

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Biliary tract cancers: current knowledge, clinical candidates and future challenges.
Tariq NU, McNamara MG, Valle JW. · · 2019 · cited 79× · PMID 31015767 · DOI 10.2147/cmar.s157092
Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Yoo C, Hyung J, Chan SL. · · 2024 · cited 19× · PMID 38638168 · DOI 10.1159/000531458
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview.
Yang W, Sun Y. · · 2021 · cited 17× · PMID 33658799 · DOI 10.2147/ott.s297643

Verify or expand the search:

Other recruiting trials for Biliary Tract Cancer

Currently open trials in the same condition.

NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03110484 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 15 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03110484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing